Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970

41.36 -1.03 -2.43%

Live - 5344 symbols - heartbeat 353s ago · 2026-10-08 02:56

After-hours 41.36 0.00%

Overnight 41.74 +0.92%

Market cap: 3.03B
P/E (TTM): -25.07
P/B: 3.39
EPS: -1.83
Div yield: 0.00%
52W pos: 56%

Reader sentiment Are you bullish or bearish on ELVN?

Anonymous reader poll. Unscientific, not investment advice.

About Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Founded: 2019
CEO: Mr. Richard A. Fair
Employees: 60
Headquarters: Boulder, Colorado, United States of America
Fiscal year end: 12-31
Website: enliventherapeutics.com

Company profile

Exchange: US
Symbol: ELVN
Market-cap rank: #2416
Listing date: 1970-01-01
Market cap: 3.03B
Float cap: 2.50B
Shares out: 73.27M
Float shares: 60.52M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 02:56:49 · For reference only, not investment advice and not tailored to your situation.